8-K: Phibro Animal Health Completes $350 Million Acquisition of Zoetis' Medicated Feed Additive Business

Phibro Animal Health Corporation finalized its acquisition of Zoetis' medicated feed additive portfolio and certain water-soluble products for $350 million, funded by new debt.

Summary

• Phibro Animal Health Corporation has completed the acquisition of Zoetis' medicated feed additive product portfolio and certain water-soluble products.
• The acquisition was finalized on October 31, 2024, for a purchase price of $350 million in cash.
• Phibro funded the acquisition by borrowing $350 million under its existing Credit Agreement, consisting of $189 million in Delayed Draw Term A-1 Loans and $161 million in Delayed Draw Term A-2 Loans.
• The acquired portfolio includes over 37 product lines sold in approximately 80 countries, six manufacturing sites, and a team of more than 300 employees.
• The acquired business is expected to enhance Phibro's profitability, EBITDA margin, and be accretive to its Adjusted Earnings Per Share.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful completion of a significant acquisition that is expected to enhance the company's financial performance and market position. The management's comments are also optimistic.

Positives

• The acquisition expands Phibro's product portfolio and geographic reach.
• The acquired business is expected to improve Phibro's financial performance, including profitability and earnings per share.
• The acquisition complements Phibro's existing product lines in vaccines, nutritional specialties, and mineral nutrition.
• The deal is expected to provide more solutions and expertise to Phibro's customers.
• The acquisition diversifies Phibro's revenue base.

Risks

• The document contains forward-looking statements that are subject to risks and uncertainties.
• Actual results may differ materially from those projected in the forward-looking statements.
• The company has taken on $350 million in debt to fund the acquisition.

Future Outlook

The acquisition is expected to boost Phibro's profitability, EBITDA margin, and be accretive to its Adjusted Earnings Per Share. Additional financial details will be provided during the Q1 earnings call on November 7th.

Management Comments

• Jack C. Bendheim, Chairman, President and Chief Executive Officer of Phibro Animal Health Corporation, stated that the acquisition marks a significant step in furthering Phibro's purpose to optimize global animal health and nutrition.
• Larry Miller, Phibro's Chief Operating Officer, noted that the acquisition is a win-win-win for customers, consumers, and investors.

Industry Context

This acquisition reflects a trend of consolidation in the animal health industry, where companies are expanding their product portfolios and geographic reach through strategic acquisitions. It positions Phibro to compete more effectively with other major players in the global animal health market.

Comparison to Industry Standards

• Zoetis, the seller, is a major player in the animal health industry, and this divestiture allows them to focus on other areas of their business.
• Other companies in the animal health sector, such as Elanco and Merck Animal Health, have also been active in acquisitions and divestitures to optimize their portfolios.
• The $350 million acquisition price is a significant investment for Phibro, and its success will depend on the integration of the acquired business and the realization of expected synergies.
• The acquisition of a portfolio with 37 product lines and 6 manufacturing sites is a substantial expansion for Phibro, comparable to other major acquisitions in the sector.

Stakeholder Impact

• Shareholders are expected to benefit from the increased profitability and earnings per share.
• Customers will have access to a broader range of products and expertise.
• Consumers will benefit from the continued safe and sustainable production of food.
• Employees of the acquired business are now part of Phibro.

Next Steps

• Phibro will file an amendment to this Form 8-K to include the financial statements and pro forma financial information related to the acquisition within 71 calendar days.
• Additional financial details will be provided during the Q1 earnings call on November 7th.

Key Dates

Keywords

acquisition, medicated feed additives, animal health, Zoetis, Phibro, water-soluble products, EBITDA, profitability, debt, manufacturing